Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1988-03-02
1989-12-12
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
548956, A61K 31675, C07D20306
Patent
active
048867900
ABSTRACT:
A method of inhibiting the replication of tumor cells is disclosed wherein Novel bis (2,2-dimethyl-1-aziridinyl)phosphinic amide antineoplastic agents of the formula: ##STR1## wherein X is R and R' are each, independently, hydrogen, alkyl, substituted alkyl, phenyl and substituted phenyl, Y is alkyl or substituted alkyl of 1-10 carbon atoms and, Z is oxygen or sulfur is administered to tumor cells.
REFERENCES:
patent: 2606900 (1952-08-01), Parker et al.
patent: 2663705 (1951-07-01), Parker et al.
patent: 2670347 (1954-02-01), Kuh et al.
patent: 3201313 (1965-08-01), Bardos et al.
Heidelberger, et al., Chem. Abstracts, vol. 52 (1958), entry 4022 h-i.
Pujman, Chem. Abstracts, vol. 51 (1957), entry 2171 d-e.
Munson, et al., Cancer Chemotherapy Reports, vol. 51(5), (1967), pp. 253-259.
Wampler et al., Absence of Cross-Resistance to Alkylating Agents in Cyclophosphamide-Resistant L1210 Leukemia, Europ. J. Cancer, vol. 14, pp. 977-982, 1978.
Bardos et al., Synthesis of Potential Dual Antagonists III, Jour. of Pharmaceutical Sciences, vol. 54, No. 2, Feb., 1965.
Chmielewicz et al., Synthesis and Chemotherapeutic Effects of Ethyl Bis-(2,2-Dimethyl)-Ethylenamido Phosphate. A Preliminary Report, Jour. of Pharmaceutical Sciences, vol. 56, No. 9, Sep. 1967.
Wodinsky et al., Combined Therapy with an Aziridine Derivative NSC 200724 (AB182) and Radiation on an Experimental Leukemia. Int. J. Radiation Oncology Biol. Phys., vol. 5, pp. 1677-1680, 1979.
Hsiao et al., Synthesis of New Bis (1-Aziridinyl) Phosphinate Alkylating Agents Containing O-Phenyl N-Phenylcarbamate Side Chains, Jour. of Med. Chem., vol. 16, p. 391, 1973.
Lalka et al., Reactions of 2,2-Dimethyl-Aziridine-Type Alkylating Agents in Biological Systems I: Colorimetric Estimation and Stability in Physiological Media, Jour. of Pharmaceutical Sciences, vol. 62, No. 8, Aug., 1973.
Bardos et al., Synthesis of Potential Dual Antagonists IV, Jour. of Pharmaceutical Sciences, vol. 54, No. 3, Mar., 1965.
Hsiao et al., Synthesis of Bis(Aziridinyl)Phosphinyl-N-Hydroxy-Urethane Derivatives as Antineoplastic Agents, Jour. of Medical Chemistry, vol. 18, p. 195, 1975.
Bardos et al., Combination of Chemotherapy with Dual Antagonists and Radiotherapy in the Treatment of Neoplastic Disease, Journal of Surgical Oncology 3(4); pp. 431-441, 1971.
Bardos et al., Structure-Activity Relationships of Alkylating Agents in Cancer Chemotherapy, Annals of the New York Academy of Sciences, vol. 163, Article 2, pp. 1006-1025, Oct. 3, 1969.
Chmielewicz et al., Alterations of Some Macromolecular and Bio Chemical Properties of Calf Thymus DNA Caused by "Dual Antagonists", and Nitrogen Mustard, Cancer Research, 27, pp. 1248-1257, Jul. 1967.
Munson et al., Preparation and Antitumor Activity of Tris (2,2-Dimethyl-1-Aziridinyl)Phosphine Oxide (Tepa-132), Cancer Chemotherapy Reports, vol. 51, No. 5, pp. 253-259, Sep. 1967.
Bardos et al., Effects of Ring-C-Methyl Substituents on the Chemical and Biological Activities of Ethylenimine Type Alkylating Agents, Int. Congress of Chemotherapy, Jun. 1967.
Bardos, Antimetabolites: Molecular Design and Mode of Action, Topics in Current Chemistry, vol. 52, pp. 90 and 92 only, 1974.
Lalka et al., Cyclophosphamide, 2,2-Dimethyl-Aziridines and Other Alkylating Agents as Inhibitors of Serum Cholinesterase, Biochemical Pharmacology, vol. 24, pp. 455-462, 1975.
Lalka et al., Reactions of 2,2-Dimethyl-Aziridine-Type Alkylating Agents in Biological Systems II: Comparative Pharmacokinetics in Dogs, Jour. of Pharmaceutical Sciences, vol. 64, No. 2, Feb., 1975.
Bardos et al., Chemical Mechanism of the Radiation Potentiating Effects of 2,2-Dimethylaziridine-Type Antitumor Agents, Int. J. Radiation Oncology Biol. Phys., vol. 5, pp. 1653-1656, 1979.
Wampler et al., Radiation Potentiating Effect of Ethyl Bis(2,2-Dimethyl-1-Aziridinyl)Phosphinate (AB-163), Int. J. Radiation Oncology Biol. Phys., vol. 5, pp. 1681-1683, 1979.
Hsiao et al., Synthesis of 5'-Thymidinyl Bis(1-Aziridinyl) Phosphinates as Antineoplastic Agents, Jour. of Med. Chemistry, vol. 24, pp. 887-889, 1981.
Zhdanov et al., Biologically Active Stable Radicals: XV.sup.1 Spin-Labeled Alkyl Carbamate-N-Phosphonic Acid Aziridides, "Synthesis", pp. 269-271, 1979.
Koneiczny et al., Methods for the Preparation of Spin-Labeled Phosphorus Compounds and Applications of Some of them to Phosphorylative Spin-Labeling, "Synthesis", Sep. 1981.
Kimler et al., Development and Testing of New Hypoxic Cell Radiosensitizers, Radiology, vol. 33, pp. 515-157, 1979.
Heidelberger, C., "The Effect of Several Phosphoramides on Transplanted Tumors", Cancer Research, 17, 277-283 (1957).
Pujman, V., "Leukemia of Mice Strain C 57 Black", Roxpravy (MPV) Ceskoslov. Akad. Ved. 66, No. 10, 1-27 (1965).
Bardos Thomas J.
MacDiarmid Joan E.
Perlman Michael E.
Cseh C. L.
Shah Mukund J.
The Research Foundation of State University of New York
LandOfFree
Novel bis(2,2-dimethyl-1-aziridinyl) phosphinic amides for use i does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Novel bis(2,2-dimethyl-1-aziridinyl) phosphinic amides for use i, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel bis(2,2-dimethyl-1-aziridinyl) phosphinic amides for use i will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2121770